Your browser doesn't support javascript.
loading
The Survival Benefit of Reabstinence After Harmful Alcohol Use Following Early Liver Transplant for Severe Alcohol-Associated Hepatitis: A Multicenter ACCELERATE Study.
Dukewich, Matthew; Dodge, Jennifer L; Lucey, Michael R; Rice, John P; Shetty, Kirti; Jakhete, Neha; Im, Gene Y; Weinberg, Ethan M; Hsu, Christine; Smith, Coleman; Ghobrial, R Mark; Therapondos, George; Shoreibah, Mohamed; Aryan, Mahmoud; Eswaran, Sheila; Fix, Oren K; Maddur, Haripriya; Terrault, Norah; Lee, Brian P.
Afiliação
  • Dukewich M; Division of Gastrointestinal and Liver Diseases, University of Southern California, Los Angeles, California, USA.
  • Dodge JL; Division of Gastrointestinal and Liver Diseases, University of Southern California, Los Angeles, California, USA.
  • Lucey MR; Department of Population and Public Health Sciences, University of Southern California, Los Angeles, California, USA.
  • Rice JP; Division of Gastroenterology and Hepatology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
  • Shetty K; Division of Gastroenterology and Hepatology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
  • Jakhete N; Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Im GY; Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Weinberg EM; Division of Liver Diseases, Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Hsu C; Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Smith C; Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Ghobrial RM; MedStar Georgetown University Hospital, Washington, District of Columbia, USA.
  • Therapondos G; Sherrie and Alan Conover Center for Liver Disease and Transplantation, Houston Methodist Hospital, Houston, Texas, USA.
  • Shoreibah M; Hepatology Section, Ochsner MultiOrgan Transplant Institute, Ochsner Medical Center, New Orleans, Louisiana, USA.
  • Aryan M; Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Eswaran S; Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Fix OK; Division of Digestive Diseases and Nutrition, Rush University Medical Center, Chicago, Illinois, USA.
  • Maddur H; Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
  • Terrault N; Division of Gastroenterology and Hepatology, University of Arizona College of Medicine, Tucson, Arizona, USA .
  • Lee BP; Division of Gastrointestinal and Liver Diseases, University of Southern California, Los Angeles, California, USA.
Am J Gastroenterol ; 2024 Jul 12.
Article em En | MEDLINE | ID: mdl-38994850
ABSTRACT

INTRODUCTION:

Early (i.e., without mandated period of abstinence) liver transplant (LT) for alcohol-associated hepatitis is the fastest-growing indication for LT in the United States and Europe. Harmful alcohol use after LT is associated with poor outcomes, but the distinction of establishing abstinence after return to drinking (i.e., reabstinence) is understudied. This study aims to characterize the survival outcomes of achieving reabstinence after post-LT harmful alcohol use.

METHODS:

We analyzed early LT recipients from 12 US LT centers between 2006 and 2021. Post-LT alcohol use was characterized as harmful using criteria of "binge" (≥5 [men] or ≥4 [women] drinks in < 24 hours) or "frequent" (≥4 days in one week) by interview or phosphatidylethanol >20 ng/mL. Reabstinence was defined as ≥12 consecutive months without harmful alcohol use after harmful alcohol use.

RESULTS:

Among 347 LT recipients (64% male, median age 43, median Model for End-Stage Liver Disease-Sodium score 38) with median post-LT follow-up of 2.2 years (interquartile interval 1.1-3.6), 276 (80%) recipients had no evidence of harmful alcohol use, 35 (10%) recipients had reabstinence, and 36 (10%) recipients had continued harmful alcohol use without reabstinence. Five-year predicted survival, adjusted for age, sex, and Model for End-Stage Liver Disease-Sodium score, was lowest among LT recipients with continued harmful alcohol use (77%), but similar among those with no harmful use (93%) and reabstinence (94%).

DISCUSSION:

Achieving reabstinence after post-LT harmful alcohol use is associated with similar 5-year post-LT survival compared with those without evidence of post-LT harmful alcohol use. Our findings highlight the importance of early detection and treatment of post-LT alcohol use.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Am J Gastroenterol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Am J Gastroenterol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos